Harada Nobuhiro, Tamura Sumihito, Sugawara Yasuhiko, Togashi Junichi, Ishizawa Takeaki, Kaneko Junichi, Aoki Taku, Sakamoto Yoshihiro, Hasegawa Kiyoshi, Tanaka Tomohiro, Yamashiki Noriyo, Kokudo Norihiro
Division of Artificial Organ and Transplantation, The University of Tokyo Hospital, Tokyo, Japan.
Division of Artificial Organ and Transplantation, The University of Tokyo Hospital, Tokyo, Japan; Organ Transplantation Service, The University of Tokyo Hospital, Tokyo, Japan.
PLoS One. 2014 Mar 5;9(3):e90462. doi: 10.1371/journal.pone.0090462. eCollection 2014.
Single nucleotide polymorphisms of interleukin-28B (IL28B) rs8099917 are reported to be associated with virologic clearance in interferon-and ribavirin -based treatment for hepatitis C virus (HCV)-infected patients. We examined virologic response in accordance with IL28B polymorphisms in our living donor liver transplantation series under a preemptive interferon and RBV treatment approach. Adequate DNA samples from both the recipient and donor for the study of single nucleotide polymorphisms of IL28B were available from 96 cases and were the subjects of the present study. Various clinical factors related with virologic response including early virologic response (EVR) and sustained virologic response (SVR) were examined. Totally 51% presented with EVR and 44% achieved SVR. Presence of the major allele (TT) in either the recipient or the donor corresponded to SVR of 53% and 48%. Presence of the minor allele (TG or GG) corresponded to SVR of 26% and 32%. Multivariate analysis revealed that genotype of HCV or EVR, but not IL28B polymorphisms in either the recipient or donor, was an independent factor for achieving SVR. When virologic response to treatment was incorporated into analysis, the impact of IL28B polymorphism on virological clearance remained relative to other factors and was not significantly independent.
据报道，白细胞介素-28B（IL28B）rs8099917的单核苷酸多态性与丙型肝炎病毒（HCV）感染患者基于干扰素和利巴韦林的治疗中的病毒学清除相关。我们在抢先性干扰素和利巴韦林治疗方法下，根据我们活体供肝移植系列中的IL28B多态性检查了病毒学反应。本研究的对象为96例患者，他们有来自受体和供体的足够DNA样本用于研究IL28B的单核苷酸多态性。我们检查了与病毒学反应相关的各种临床因素，包括早期病毒学反应（EVR）和持续病毒学反应（SVR）。共有51%的患者出现EVR，44%的患者实现SVR。受体或供体中主要等位基因（TT）的存在对应的SVR分别为53%和48%。次要等位基因（TG或GG）的存在对应的SVR分别为26%和32%。多变量分析显示，HCV基因型或EVR是实现SVR的独立因素，而受体或供体中的IL28B多态性不是。当将治疗的病毒学反应纳入分析时，IL28B多态性对病毒学清除的影响相对于其他因素仍然存在，且并非显著独立。
